Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

44.50USD
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
$44.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
191,691
52-wk High
$67.86
52-wk Low
$29.17

Conway, Charles 

Dr. Charles Conway, Ph.D., serves as Chief Scientific Officer of the Company. Dr. Conway has served as our chief scientific officer since January 2017. From January 2000 to January 2017, he held positions of increasing responsibility in drug discovery at BMS, most recently serving as associate director—biology analytics. Dr. Conway led BMS’s biology program efforts working on the CGRP antagonist program for over 10 years and was part of the full development team advancing rimegepant into clinical research. Dr. Conway has extensive experience in the field of pain research and is an inventor on three U.S. patents granted for the treatment of pain. Prior to his time at BMS, Dr. Conway was a postgraduate research anesthesiologist at the University of California San Diego. Dr. Conway received his B.S. in experimental psychology from the University of Central Missouri and his Ph.D. in neuroscience from the University of California Santa Barbara.

Basic Compensation

Total Annual Compensation, USD 2,783,920
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 8,932
Fiscal Year Total, USD 2,792,860

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

706,360

Vlad Coric

7,854,000

James Engelhart

3,217,070

Kimberly Gentile

2,784,540

Charles Conway

2,792,860

Robert Berman

521,060
As Of  31 Dec 2018